Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC
Combining the bispecific antibody amivantamab (Rybrevant) with chemotherapy in the first- or second-line setting offers ongoing benefit to patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer (NSCLC) even after …